All Articles

An analysis of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies was presented by Pashtoon Kasi, MD, MS.

Two phase 1a/1b dose-escalation/expansion trials investigated the efficacy and safety of MDM2-p53 antagonist BI 907828 in patients with advanced biliary tract cancer.

CTX-009 in combination with paclitaxel showed encouraging efficacy in patients with advanced biliary tract cancer.

Gunagratinib is being investigated in an ongoing phase 2a dose-expansion study in patients with cholangiocarcinoma.

Results of the SWOG 1815 study failed to demonstrate a benefit with the addition of nab-paclitaxel to gemcitabine/cisplatin (GemCis) versus GemCis alone.

In the JCOG1202 subgroup analysis, researchers analyzed risk factors for early relapse in patients with biliary tract cancer undergoing surgical resection.

Researchers aimed to assess characteristics, outcomes, and genomic profiles of long-term survivors treated with durvalumab plus gemcitabine/cisplatin (GemCis) or placebo plus GemCis in the TOPAZ-1 trial.

IMbrave 151 examined the efficacy of the PD-L1 inhibitor atezolizumab with or without the VEGF inhibitor bevacizumab, and gemcitabine/cisplatin as first-line treatments in patients with advanced biliary tract cancer.

A single-arm, phase 2 study investigated the safety and efficacy of second-line nab-paclitaxel combined with the anti–PD-1 antibody sintilimab in patients with advanced biliary tract cancer.

This phase 2 randomized trial assessed stereotactic body radiation and the anti–PD-1 drug nivolumab with or without the anti-CTLA4 drug ipilimumab in patients with metastatic biliary tract cancer.